Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Obinutuzumab/chlorambucil gives OS benefit over rituximab in frontline CLL

Valentin Goede • 15 Jun 2018
EHA 2018
Chronic Lymphocytic Leukemia Leukemia Antibodies Chlorambucil Obinutuzumab Rituximab
CLL11

Exciting updates on obinutuzumab were presented at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Final analysis results from the CLL11 study (NCT01010061) were presented at the press briefing by Dr Valentin Goede, of the German CLL Study Group, Cologne, Germany. Dr Goede highlights the overall survival benefit of obinutuzumab plus chlorambucil over rituximab in patients with chronic lymphocytic leukemia (CLL) and comorbidities.

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals